Affiliation:
1. Medical Department, Max Zeller Söhne AG, 8590 Romanshorn, Switzerland
2. Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital—University Hospital, 3010 Bern, Switzerland
Abstract
Cimicifuga racemosa (CR) extracts contain diverse constituents such as saponins. These saponins, which act as a defense against herbivores and pathogens also show promise in treating human conditions such as heart failure, pain, hypercholesterolemia, cancer, and inflammation. Some of these effects are mediated by activating AMP-dependent protein kinase (AMPK). Therefore, comprehensive screening for activating constituents in a CR extract is highly desirable. Employing machine learning (ML) techniques such as Deep Neural Networks (DNN), Logistic Regression Classification (LRC), and Random Forest Classification (RFC) with molecular fingerprint MACCS descriptors, 95 CR constituents were classified. Calibration involved 50 randomly chosen positive and negative controls. LRC achieved the highest overall test accuracy (90.2%), but DNN and RFC surpassed it in precision, sensitivity, specificity, and ROC AUC. All CR constituents were predicted as activators, except for three non-triterpene compounds. The validity of these classifications was supported by good calibration, with misclassifications ranging from 3% to 17% across the various models. High sensitivity (84.5–87.2%) and specificity (84.1–91.4%) suggest suitability for screening. The results demonstrate the potential of triterpene saponins and aglycones in activating AMP-dependent protein kinase (AMPK), providing the rationale for further clinical exploration of CR extracts in metabolic pathway-related conditions.
Reference44 articles.
1. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers;Wuttke;Maturitas,2003
2. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms;Osmers;Obstet. Gynecol.,2005
3. Dose-dependent effects of the Cimicifuga racemosa extract Ze450 in the treatment of climacteric complaints: A randomized, placebo-controlled study;Schellenberg;Evid. Based Complement. Altern. Med.,2012
4. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints—An observational study;Drewe;Phytomed. Int. J. Phytother. Phytopharm.,2013
5. HMPC (2018). European Union Herbal Monograph on Cimicifuga racemosa (L.) Nutt., Rhizoma, European Medicines Agency.